Please assess the completion status of the following clinical trial:

Trial Title: Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Female or male patients ≥18 years with WHO performance status ≤ 1~* HER-2 overexpressing metastatic breast cancer cells confirmed by histology~* Progressive disease on prior trastuzumab alone/or in combination with other anticancer agents, or relapsed any time after completion of this therapy~* Patients neurologically stable with adequate bone marrow, liver and renal function~Exclusion criteria:~* Patients receiving endocrine therapy for breast cancer ≤ 2 weeks prior to study treatment start~* Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have received these ≤ 4 weeks prior to study treatment start or patients who have received lapatinib ≤ 2 weeks prior to study treatment start~* Patients who have previously received vinorelbine or mTOR inhibitors~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 Daily Schedule (Type: EXPERIMENTAL): 5mg or 10mg
- RAD001 Weekly Schedule (Type: EXPERIMENTAL): 30mg

Based on this trial design, predict the completion outcome and termination type (if applicable).